The objective of the study was to determine the effectiveness and the toxicity of a combined chemotherapy consisting of cladribine (2-CdA), mitoxantrone and cyclophosphamide (CMC regimen) in the treatment of previously untreated B cell chronic lymphocytic leukemia (B-CLL). From August 1998 to December 2000 2-CdA was administered at a dosage of 0.12 mg/kg for 3 (CMC3) or 5 (CMC5) consecutive days, mitoxantrone at 10 mg/m 2 on day 1 and cyclophosphamide at 650 mg/m 2 on day 1 to 62 patients with advanced or progressive B-CLL. The cycles were repeated at 4 week intervals or longer if severe myelosuppression occurred. Twenty patients received CMC5 and 42 patients CMC3. Within the analyzed group an overall response (OR) rate (CR+PR) of 64.5% (95% CI: 52.7-76.3%) was reported, including 29.0% CR. There was no difference in the CR rate between the patients treated with CMC5 (30%) and CMC3 (28.6%) (P = 0.9), nor in the OR rate (55.0% and 69.0%, respectively, P = 0.3). Residual disease was identified in seven out of 18 (38.9%) patients who were in CR, including two treated with CMC5 and five treated with CMC3 protocols. CMC-induced grade III or IV thrombocytopenia occurred in 12 (19.4%) of patients, including four (20%) CMC5-treated and eight (19%) CMC3-treated patients (P = 0.8). Neutropenia grade III or IV was observed in seven (35%) and 11 (26.2%) patients, respectively (P = 0.8). Severe infections, including pneumonia and sepsis, occurred more frequently after CMC5 (11 patients, 55.0%) than CMC3 (10 patients, 28.6%) (P = 0.03) Fourteen patients died, including six treated with CMC5 and eight treated with CMC3 (30% and 19%, respectively). Infections were the cause of death in nine patients, including four in the CMC5 group and five in the CMC3 group. In conclusion, our results indicate that the CMC programme is an active combined regimen in previously untreated B-CLL patients; its efficiency seems to be similar to that observed earlier in B-CLL patients treated with 2-CdA as a single agent. However, toxicity, especially after CMC5 administration, is significant. Therefore, we recommend the CMC3 but not the CMC5 programme for further evaluation. Leukemia (2001Leukemia ( ) 15, 1510Leukemia ( -1516 
Introduction
The newer purine analogs, fludarabine (FAMP), 2Ј-deoxycoformycin (DCF) and cladribine (2-chlorodeoxyadenosine, 2-CdA), have been synthesized recently and introduced into the treatment of low-grade lymphoid malignancies. nucleoside analog with a substituted halogen atom at position 2 in its purine ring, which makes it resistant to deamination by adenosine deaminase. It is mainly used in the treatment of hairy cell leukemia, but it is also highly active in chronic lymphocytic leukemia (CLL), with an overall response rate (OR) and complete remission rate (CR) comparable to that achieved with FAMP. [4] [5] [6] [7] There are some opinions that 2-CdA is associated with more frequent and problematic myelosuppression. However, direct comparison of both agents in the randomized study of CLL patients has not been published as of this time.
Despite the fact that new purine analogs induce a higher overall response rate and a higher CR rate in patients with CLL, they do not influence survival time. 5, 8 On the other hand, both FAMP and 2-CdA administered as single agents can induce immunophenotypic and molecular remission, which is especially important in younger patients in order to qualify these patients for bone marrow transplantation and offer the possibility of recovery. 3, 9 Combined use of purine analogs with other cytotoxic agents may increase the CR rate and, possibly, suppress minimal residual disease and prolong survival. Some preclinical studies and early clinical reports may support such a hypothesis. [10] [11] [12] [13] [14] [15] [16] Among cytotoxic agents, alkylating drugs and anthracyclines were the primary candidates for use in combination with purine analogs. Synergistic action of 2-CdA with cyclophosphamide and its derivatives has been shown both in in vitro and in vivo experiments. 10, 11 These results have been confirmed recently by early clinical trials, which have shown that the combination of 2-CdA with cyclophosphamide and prednisone is feasible and active in patients with CLL and other low-grade lymphoid malignancies. 13, 14 Mitoxantrone is also a useful drug in the treatment of lowgrade lymphomas and can be combined with purine analogs. [17] [18] [19] [20] However, the advantage of such a combination in patients with refractory or relapsing disease over 2-CdA alone has not yet been proven. Thus, the combination of 2-CdA with cyclophosphamide and mitoxantrone seems to be the logical conclusion of the clinical studies in which 2-CdA was administered with each independently. In our previous study, 21 we showed that combined treatment with 2-CdA, cyclophosphamide and mitoxantrone (CMC programme) in heavily pretreated CLL and other indolent lymphoma patients is an active regimen. In this report, we present our experience with the combination of 2-CdA with cyclophosphamide and mitoxantrone in previously untreated patients with B-CLL.
Patients and methods

Patients
Between August 1998 and December 2000, 62 previously untreated patients with progressive or symptomatic CLL were treated with a combined chemotherapy consisting of 2-CdA, cyclophosphamide and mitoxantrone. The characteristics of the patients are shown in Table 1 . All of the patients fulfilled the National Cancer Institute-Sponsored Working Group criteria for CLL. 22 Pretreatment evaluation included examination of medical history, physical examination, complete blood cell count, differential count of WBC, chemical survey, bone marrow examination and serum immunoglobulin level quantitation. Cytogenetic analysis was not routinely performed. The patients had peripheral lymphocytosis greater than 10 × 10 9 /l and more than 30% lymphocytes in normal or hypercellular bone marrow. The differences between mean values in both groups of patients were not significant. Cell marker studies were performed to confirm B cell origin and monoclonal proliferation. All patients were CD5, CD19, CD20 and CD23 positive and showed monoclonality for light chain immunoglobulin membrane surface receptors.
The clinical stage of disease was determined at the time of initiation of the treatment according to Rai's classification. 23 The distribution is shown in Table 1 . Patients in stage 0, I and II were eligible if they had evidence of active disease, including progressive lymphocytosis, massive splenomegaly or bulky lymphadenopathy, recurrent disease-related infections, weight loss Ͼ10% over a 6 month period, temperature of 38°C related to disease or extreme fatigue. Patients with poor performance status (WHO scale 4), active infection, abnormal liver or renal function and Richter's syndrome were excluded from the study. The study was approved by Local Ethical Committees and the patients had signed the informed consent form.
Treatment modality
The doses and schedule of the treatment agents were based on previous studies in cases of CLL relapse, refractory CLL or low-grade lymphoma. 7, [19] [20] [21] In the first part of the study, CMC protocol consisted of 2-CdA administered at a dose 0.12 mg/kg in 2-h i.v. infusion for 5 (CMC5) days, mitoxantrone 10 mg/m 2 i.v. on day 1 and cyclophosphamide 650 mg/m 2 i.v. on day 1. In the second part of the study, 2-CdA administration was shortened to 3 days (CMC3) because of excessive hematological toxicity of CMC5 protocol. The doses of mitoxantrone and cyclophosphamide were the same as in the CMC5 protocol. 2-CdA (Biodrybin) was synthesized according to the method of Kazimierczuk et al 24 and was commercially available from the Institute of Biotechnology and Antibiotics-Bioton (Warsaw, Poland).
The cycles were repeated over 28 days for three courses. If hematological complications (thrombocytopenia Ͻ50 × 10 9 /l, granulocytopenia Ͻ0.5 × 10 9 /l) or severe infections developed the drugs were re-administered at time intervals longer than 28 days, ranging from 2 to 4 months, until the increase of hematological parameters or recovery from infections was noted. If a response had been documented, patients were treated until maximal response or prohibitive toxicity. If no response or progression of the disease was observed after three cycles, the treatment was discontinued. Packed red cells were transfused for symptomatic anemia or prophylactically if the hemoglobin level was lower than 7.0 g/dl. Platelets were administered prophylactically if the platelet count was less than 15.0 × 10 9 /l. Blood products were irradiated. In order to prevent hyperuricemia, allopurinol (300 mg/daily) was administered. No patients received antibiotics or antiviral agents prophylactically. No patients received hematopoietic growth factors prophylactically but G-CSF or GM-CSF were administered if the absolute granulocyte count was less than 1.0 × 10 9 /l and active infection was present.
Response criteria
Treatment effect was monitored by physical examination, blood count evaluation and bone marrow examination before and after every course of chemotherapy. Guidelines for response were those developed by the NCI-Sponsored Working Group. 22, 25 Complete response (CR) required the absence of symptoms and organomegaly, normal complete blood cell count (absolute neutrophil count Ͼ1.0 × 10 9 /l, hemoglobin Leukemia concentration Ͼ11.0 g/dl, platelet count Ͼ100 × 10 9 /l and bone marrow with less than 30% lymphocytes for at least 2 months. Partial response (PR) was considered in the case of a 50% or greater decrease in the size of lymph nodes, liver and spleen, and peripheral blood findings either identical to those of CR or improved over pre-therapy values by at least 50%.
The patients who had not achieved CR or PR were classified as non-responders (NR). Clinical relapse was defined according to Robertson et al 9 as an increase in the absolute lymphocyte count above 10 × 10 9 /l, more than 50% increase in the sum of the size of at least two lymph nodes, appearance of new lymph nodes, more than a 50% increase in the liver or spleen below the costal margin, the new appearance of palpable hepatosplenomegaly or development of an aggressive lymphoma.
Immunophenotype analysis
Immunophenotyping was performed on peripheral blood and bone marrow by flow cytometry using a simultaneous dualcolor staining technique before treatment and after obtaining CR, according to the method described by Brugiatelli et al. 26 A combination of phycoerythrin (PE)-conjugated and fluorescent isothiocyanate (FITC)-conjugated monoclonal antibodies was utilized. Residual disease was determined by co-expression of CD5/CD19 and CD5/CD20 on B lymphocytes in conjunction with monoclonality of surface light-chain expression on CD5-positive B cells. The presence of more than 10% of the total lymphocytic population co-expressing CD5/CD19 and CD5/CD20 with monotypic light-chain expression (a : or : ratio exceeding 3:1) was considered positive for residual disease, according to the criteria developed by Robertson et al. 9 
Toxicity monitoring
Hematological toxicity was evaluated according to the criteria developed by the NCI-Sponsored Working Group. 22 Druginduced anemia, thrombocytopenia and neutropenia were diagnosed if after the treatment course a further decrease of hemoglobin level and/or platelets and neutrophils numbers were observed. Other side-effects were assessed and monitored according to WHO criteria. 27 Only major and moderate infections were recorded, including life-threatening episodes such as pneumonia and disseminated infections that required oral or parenteral antibiotic therapy, antifungal and antiviral therapy and/or hospitalization. Fever of unknown origin (FUO) requiring parenteral antibiotic therapy was also recorded as an infectious event.
Infections were reported as CMC related if they developed on therapy or within 4 months of the completion of the CMC treatment.
Statistical analysis
Statistical analysis of the differences in the percentages of responses in patients treated with CMC3 and CMC5 were evaluated by the 2 test. Ninety-five percent confidence intervals for response probability were calculated using the method described by Duffy and Santner.
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Results
Sixty-two patients with B-CLL entered the study and all of them were analyzed. The median time from the diagnosis to CMC administration was 8.2 months (range 4-26). The characteristics of the patients are presented in Table 1 . Twenty patients were treated according to CMC5 protocol and 42 received CMC3 chemotherapy. The total number of CMC courses administered to the entire group of patients amounted to 237 (84 CMC5 and 153 CMC3 courses). The median number of CMC3 courses was 3.8 (range 1-6), and the median time needed to deliver the total number of cycles was 4.6 months (range 1-8.7). The patients treated with CMC5 received from 1 to 6 (median 2.5) courses, and the median time needed to deliver the total number of cycles was 5.7 months (range 1-10.2). In the CMC3 group 8 (19%) patients, and in the CMC5 group 9 (45%) patients, could not reach the total of three cycles because of early death or severe myelotoxicity.
The criteria for CR were fulfilled in 18 patients (29.0%) and PR in 22 (35.5%), giving an overall response rate in 64.5% (95% CI 52.7-76.3%) of total patients (Table 2 ). There were no differences in the frequency of OR between the CMC5-and the CMC3-treated groups (55% and 69%, respectively, P = 0.3). The CR rate was also similar in both groups (30% and 28.6%, respectively) (P = 0.9). In the group treated with CMC5 the patients attaining CR received a median of three courses (range 2-6) and in the group treated with CMC3 a median of three courses (range 2-6) was also administered. CRs were observed more frequently in the early stages of the disease (Rai 0, I and II) -11/29 (37.9%) than in the more advanced stages (Rai III and IV) -7/33 (21.2%) (P = 0.8).
Surface immunophenotyping by flow cytometry using dualcolor staining on peripheral blood and/or bone marrow was performed in patients who achieved CR. Residual disease was identified in seven out of 18 (38.9%) patients who achieved remission.
Toxicity
Myelosuppression was the major toxicity of the CMC therapy (Table 3) . Grades III and IV neutropenia were observed in 18 (29.0%) out of 62 patients and after 30 (12.7%) out of 237 CMC courses. There was no significant difference between the frequency of severe neutropenia in the 7/20 (35%) patients treated with CMC5 or 11/42 (26.2%) patients treated with CMC3 regimens (P = 0.8). Hematopoietic growth factors (G-CSF or GM-CSF) were administered after four and 13 courses, respectively. The frequency of thrombocytopenia was similar (20% and 19%) in both groups (P = 0.8). Grade III or IV anemia was the rarest hematological complication and was observed in only four patients. Autoimmune hemolytic anemia (AIHA) developed in two patients treated with CMC3. These patients had no clinical or laboratory symptoms of this complication before CMC treatment.
Severe infections and fever of unknown origin (FUO) requiring parenteral antibiotic therapy occurred more often in patients treated with the CMC5 regimen -11 patients (55%) than CMC3 -10 patients (23.8%) (P = 0.03). The number of severe infections and FUO was also more frequent after CMC5 courses -15 (17.9%) than CMC3 courses -12 (7.8%) (P = 0.03). Pneumonia and upper respiratory infections (sinusitis and bronchitis) occurred in 23 patients, including 12 treated with CMC5 and 11 treated with CMC3. Herpes zoster reactivation and herpes simplex infections were observed in 10 patients (two after CMC5 and eight after CMC3). Tuberculosis was diagnosed in one patient after two courses of CMC5. Other opportunistic infections were not seen.
In four patients, grade III vomiting according to the WHO classification was observed and in one DIC syndrome developed. Other non-hematological side-effects including alopecia, abnormal aminotransferases, transient increased LDH and creatinine levels were observed only very rarely (Table 4) . Secondary cancers were observed in two patients including one case of pulmonary cancer (adenocarcinoma) after CMC3 in a patient without the history of tobacco exposure and one case of malignant histiocytosis after CMC5. Richter syndrome has not been observed to date
The intervals between CMC courses due to myelosuppression and/or infections were prolonged from 4 to 8 weeks in 23 (37%) patients and after 38 (16%) courses, including 10 patients (18 courses) treated with CMC5 and 13 patients (20 courses) treated with CMC3. In four patients (two treated with CMC5 and two with CMC3), therapy was stopped before the completion of three courses of treatment because of prolonged severe myelosuppression.
Altogether, 14 (22.6%) patients died during the study, including six (30%) treated with CMC5 and eight (19.0%) with Leukemia CMC3. All six patients in the CMC5 group died before completing three courses of treatment. In CMC3 group six out of eight patients died before completing three courses of treatment. The causes of death are shown in Table 5 . Complications due to infections were the cause of death in nine patients, including four treated with CMC5 and five after CMC3 therapy.
Discussion
In spite of intensive research and important progress in the last years, CLL still remains incurable. The results of the randomized studies published so far indicate that both FAMP and 2-CdA, applied as first-line therapy, significantly increase the rate of complete remissions when compared to chlorambucil, which is still regarded as the gold standard in CLL treatment. 5, 8 However, neither study proved that the higher remission rate is translated into longer survival. That is why further research is justified, with the objective to increase the remission rate and quality, and in this way, to influence survival time. In the trials finished to date, alkylating drugs and anthracyclines with mitoxantrone were most often combined with either FAMP or with 2-CdA. [10] [11] [12] [13] [14] [15] [16] [17] [18] 29, 30 Our study is the first, to our knowledge, in which previously Table 4 CMC-induced grade III and IV non-hematological side-effects n, number of patients; n1, number of courses; FUO, fever of unknown origin; DIC, disseminated intravascular coagulation; IHD, ischemic heart disease. untreated CLL patients received two other drugs in combination with 2-CdA: cyclophosphamide and mitoxantrone (CMC programme). In this study, the daily doses of 2-CdA (0.12 mg/kg) were identical in both groups, but the duration of the treatment was different: 3 days (CMC3) or 5 days (CMC5). The doses of cyclophosophamide and mitoxantrone were the same in both programmes. Our study indicates that CMC combination is active in CLL. The CR rate was 29% and the OR rate was 64.5%. It should be emphasised, that in spite of the large proportion of patients who have responded to treatment, the response rate does not seem greater than in our earlier studies with 2-CdA in monotherapy or combined with prednisone. 7, 8 It is of interest that the shortened administration time from 5 (CMC5) to 3 (CMC3) days has not resulted in a lower CR rate (30% and 28.6%, respectively) or overall response rate (55% and 69%, respectively). Similarly, we observed earlier the lack of influence of a shorter administration time of 2-CdA within a CMC programme on the outcome in pretreated indolent lymphoma. 21 Previous studies revealed that the response rate was not lower when 2-CdA or FAMP were combined with either cyclophosphamide, 14, [31] [32] [33] mitoxantrone 17, 34 or anthracycline. 35 Minimal residual disease (MRD) was evaluated by twocolor immunophenotyping in the patients who fulfilled morphological criteria for CR. MRD was identified in seven out of 18 patients (38.9%). A similar evaluation was performed in the CLL patients treated with 2-CdA in monotherapy and MRD was diagnosed in five out of 17 (29.4%) patients with CR. 3 These data indicate that the combined therapy with CMC does not appear to reduce the incidence of MRD more than 2-CdA in monotherapy.
To the best of our knowledge, our study is the first in which a purine analog was combined with two other cytostatics in patients with CLL or low-grade non-Hodgkin's lymphoma as first-line treatment. Such combinations were, however, administered to earlier pretreated patients. 21, 36, 37 These were the phase I/II studies that did not prove that the combination of purine analog with cyclophosphamide and mitoxantrone seemed more efficient that the monotherapy with FAMP or 2-CdA.
An additional aim of our study was the evaluation of the treatment-related toxicity of the CMC programme. We have shown that the most important toxic effect of this combination was myelosuppression. Grade III/IV neutropenia was observed in 29% of the patients and severe thrombocytopenia in 19.4% of the patients. It should be remembered, though, that myelotoxicity is the limiting factor for the administration of any drug of the CMC programme when they are applied in monotherapy or combined with other cytotoxic agents. Important myelotoxicity of the CMC programme may indicate the necessity of reducing the dose of 2-CdA in this combination, and this supports the CMC3 rather than the CMC5 programme. The justification of such an approach has also been found in other studies, where the dose of purine analog in combination was lower than in monotherapy. [16] [17] [18] 29, 38 The infections were frequent in the patients treated with the CMC programme and they were most commonly the cause of death. These results are consistent with the observations from other studies, which also indicate that infections are frequent in patients treated with purine analogs. 39, 40 It should be emphasized that the frequency of infections was significantly lower in patients treated with CMC3 (23.8%) than in patients treated with CMC5 (55%) (P = 0.02). Betticher et al 41 found that the reduction in the dose of 2-CdA from 0.7 mg/kg per cycle to 0.5 mg/kg per cycle in pretreated patients with malignant lymphomas did not decrease the activity of this compound but greatly reduced the incidence of infections.
Further reduction of myelosuppression and infections may be most likely achieved with the prophylactic use of growth factors following the chemotherapy cycle. 42, 43 In our study, G-CSF was applied only as a treatment for severe infections to the patients with neutropenia Ͻ1.0 × 10 9 /l. O'Brien et al 42 showed, however, that prophylactic administration of G-CSF to patients treated with FAMP may reduce the incidence of pneumonia, but does not interfere with other infections. It should also be remembered that prophylactic administration of hemopoietic growth factors may greatly increase the cost of treatment. As an alternative, some authors are in favor of prophylaxis with antibacterial and antiviral agents in patients treated with purine analogs. 44, 45 This approach is intended to reduce the incidence of opportunistic infections. We have not, however, observed in our patients infections caused by Pneumocystis carinii or other opportunistic infections. Such an approach should also not be recommended because of the broad spectrum of potential infections that may necessitate the use of numerous potentially toxic drugs. 46 In conclusion, combined treatment with 2-CdA, mitoxantrone and cyclophosphamide (CMC programme) shows significant therapeutic activity in previously untreated patients with CLL. However, the toxicity of the CMC programme is significant although it is restricted mainly to myelosuppression and infections. The reduction of total dose of 2-CdA per cycle in the CMC programme does not seem to decrease its antileukemic activity but significantly reduces the risk of infections. At present, it is not clear whether the CMC programme is more efficient in comparison to 2-CdA in monotherapy or the combination of 2-CdA with cyclophosphamide in previously untreated CLL patients. Nevertheless, in our opinion, the CMC3, but not the CMC5 programme, deserves further evaluation.
